Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616768 | 0.94 | GSK3B (0.45) | GSK3BEPHX1CCNA2CDK2MAPT | |
| SCHEMBL12680401 | 0.85 | BCHE (0.43) | GSK3BBCHECCNA2CDK2MAPT | |
| SCHEMBL3601483 | 0.82 | GSK3B (0.56) | GSK3BCCNA2CDK2MAPTL3MBTL1 | |
| SCHEMBL12680400 | 0.81 | MAPT (0.40) | GSK3BEPHX1BCHECCNA2CDK2 | |
| SCHEMBL6609299 | 0.78 | GSK3B (0.56) | GSK3BCCNA2CDK2MAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3607549 | 0.77 | GSK3B (0.55) | GSK3BCCNA2CDK2MAPTL3MBTL1 | |
| SCHEMBL7991074 | 0.76 | BCHE (0.43) | GSK3BEPHX1BCHEMALT1MEN1 | |
| SCHEMBL4554916 | 0.76 | GSK3B (0.49) | GSK3BCCNA2CDK2MAPTL3MBTL1 | |
| SCHEMBL6617607 | 0.72 | CDK5 (0.62) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL7490071 | 0.72 | CA1 (0.43) | EPHX1BCHEGFERMALT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| EP-2137188-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Pharma AG (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2008113469-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-25 | — | — | WO | disclosed |
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | US | disclosed |
| EP-1417188-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | Novo Nordisk A/S (DK) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003011843-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | GSK3B 3269/4885EPHX1 3492/4885BCHE 3755/4885 |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | THPO, TYMP, TPMT | GSK3B 3009/4885EPHX1 3184/4885BCHE 4005/4885 |
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | GSK3B, GSK3A, GYS2 | GSK3B 1/4885EPHX1 3978/4885BCHE 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.